A genome-wide CRISPR/Cas9 screen identifies DNA-PK as a sensitiser to <sup>177</sup>Lutetium-DOTA-octreotate radionuclide therapy.

Theranostics · 2023 · PMC10526672 · PMID 37771787

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

While there were no biological pathways enriched by Gene Ontology (GO) pathway analysis in the 6 selected candidates from the resistance arm of the screen, two highly significant genes were identified, ARRB2 (coding for Beta-Arrestin 2) and MVP (Major Vault Protein) (blue dots in 1E).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.